Science News
From gut flora to fermented milk, his discoveries still shape modern microbiome science.
At the upcoming Probiotic, Prebiotic and New Food Congress, Professor Willem de Vos, University of Helsinki, will explore emerging insights into the role of dietary fibers and their transformation into…
Targeting TudS could be a potential therapeutic approach for treating C. difficile infections.
Each Fusobacterium nucleatum population has unique traits and distribution patterns across body sites and conditions such as colorectal cancer and Crohn’s disease.
Gut microbiota-produced bile acids can be used as therapeutic targets for multiple sclerosis.
Probiotic supplementation improves sports performance by enhancing nutrient absorption, immune function, and endurance while reducing anxiety and gastrointestinal symptoms.
At the upcoming 13th edition of the Probiotics, Prebiotics, and New Food Congress in Rome, Professor Emma Allen-Vercoe, PhD from the University of Guelph (Canada), will present groundbreaking research on…
Targeting E. lenta or boosting neutrophil function may lead to new treatment strategies for bronchiectasis and related lung diseases.
Nutrient competition is the main mechanism of C. difficile inhibition, hinting at the potential for targeted therapies with probiotics instead of traditional FMT.
Introducing more natural microbes could improve astronauts’ health.
Researchers have developed new tools to better understand the role of Bifidobacterium breve, revealing its competitive growth strategies and potential for supporting the immune system.
Delayed microbiota maturation in infants with cystic fibrosis could contribute to disease complications, highlighting potential therapeutic targets.
Understanding the complex interactions between exercise, diet and gut health can help to develop approaches to influence the gut microbiota, boost immunity and prevent or manage gastrointestinal diseases.
Professor Jacques Ravel, from University of Maryland School of Medicine and LUCA Biologics, discusses his latest research and therapeutic innovations in the field of vaginal microbiome modulation.
Phages could be used as a drug delivery system for conditions such as inflammation and obesity.
Microbiota analysis could help sexual assault investigations by detecting microbial markers of contact, even in cases where traditional DNA evidence is lacking.
Celine Druart, from the Pharmabiotic Research Institute, discusses the new European regulation concerning substances of human origin and the impact on microbiome research and therapeutic development.
L-ornithine can be an additional therapy to boost the efficacy of ustekinumab in people with Crohn’s disease.
By addressing biases and increasing diversity in microbiota studies, researchers can develop more accurate and inclusive health strategies for women of different backgrounds.
Matthew Cheng, CEO of Kanvas Biosciences, introduces the company’s cutting-edge spatial biology platform, developed to provide deeper insights into host-microbiome interactions.
